<DOC>
	<DOCNO>NCT01036035</DOCNO>
	<brief_summary>THVD-201 novel combination muscarinic antagonist ( tolterodine ) muscarinic agonist ( pilocarpine ) .</brief_summary>
	<brief_title>Effects Novel Combinations Tolterodine/Pilocarpine Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Tolterodine Healthy Subjects</brief_title>
	<detailed_description>Because limitation take two medication separate period time minimise adverse event , two novel formulation develop improve compliance ease administration . This study evaluate formulation term pharmacokinetic profile effect SSF . In addition , effect combination entity urine frequency safety/tolerability assess .</detailed_description>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>Healthy male , 18 45 year age . BMI 2030 m2 . Subjects history sensitivity antimuscarinic muscarinic agent related derivative . Clinically significant ECG , vital sign clinical laboratory index .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Tolterodine</keyword>
	<keyword>Over active Bladder ( OAB )</keyword>
	<keyword>Incontinence</keyword>
</DOC>